Get the Stockscreener App
4.51
2.06%
-0.095
After Hours:
4.53
0.02
+0.44%
Onkure Therapeutics Inc stock is traded at $4.51, with a volume of 180.87K.
It is down -2.06% in the last 24 hours and up +19.31% over the past month.
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
See More
Previous Close:
$4.605
Open:
$4.63
24h Volume:
180.87K
Relative Volume:
0.67
Market Cap:
$61.67M
Revenue:
-
Net Income/Loss:
$-59.52M
P/E Ratio:
-1.0239
EPS:
-4.4049
Net Cash Flow:
$-51.87M
1W Performance:
+2.97%
1M Performance:
+19.31%
6M Performance:
+51.85%
1Y Performance:
+50.33%
1-Day Range:
$4.40
$4.685
1-Week Range:
$3.97
$4.6999
52-Week Range:
$1.70
$4.75
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Name
Onkure Therapeutics Inc
Sector
Industry
Phone
(720) 307-2892
Address
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
4.51 | 62.97M | 0 | -59.52M | -51.87M | -4.4049 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-25 | Initiated | Evercore ISI | Outperform |
| Dec-05-24 | Initiated | Leerink Partners | Outperform |
| Oct-10-24 | Initiated | Oppenheimer | Outperform |
| Dec-15-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-15-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-14-23 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-23 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Dec-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-14-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-14-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-15-23 | Initiated | William Blair | Outperform |
| Aug-28-23 | Initiated | H.C. Wainwright | Buy |
| Jul-03-23 | Initiated | BofA Securities | Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jan-27-22 | Initiated | Robert W. Baird | Outperform |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-22-21 | Initiated | Ladenburg Thalmann | Buy |
| May-04-21 | Initiated | Jefferies | Buy |
| May-04-21 | Initiated | Piper Sandler | Overweight |
| May-04-21 | Initiated | SVB Leerink | Outperform |
View All
Onkure Therapeutics Inc Stock (OKUR) Latest News
Revenue Check: Whats the profit margin of OnKure Therapeutics Inc2026 Volume Leaders & Growth-Oriented Investment Plans - baoquankhu1.vn
Growth Recap: Is Vistra Corp gaining market shareQuarterly Trade Summary & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Access Industries (OKUR) discloses 19.99% OnKure stake and board right - Stock Titan
StepStone affiliates report 2.66M shares in OnKure (NASDAQ: OKUR) - Stock Titan
RA Capital group reports 9.99% stake in OnKure (NASDAQ: OKUR) - Stock Titan
Trails Edge holds 6.0% of OnKure (NASDAQ: OKUR) after private placement - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Trading Recap: Whats the profit margin of OnKure Therapeutics Inc2026 Biggest Moves & AI Driven Price Forecasts - baoquankhu1.vn
LifeSci Capital Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Cuts Target Price to $16 - 富途牛牛
Breakouts Watch: Can OnKure Therapeutics Inc deliver consistent EPS growthDay Trade & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
OKUR SEC FilingsOnKure Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
OnKure (OKUR) CEO Nicholas Saccomano awarded 330,000 stock options - Stock Titan
OnKure (OKUR) CFO granted 110,000 stock options at $4.07 - Stock Titan
OnKure Therapeutics (OKUR) awards 110,000 options to Chief Scientific Officer - Stock Titan
OnKure (OKUR) grants CMO 110,000 stock options at $4.07 strike - Stock Titan
OnKure (OKUR) director receives 15,300 stock options at $4.14 strike price - Stock Titan
OnKure Therapeutics (OKUR) director Liam Ratcliffe submits Form 3 insider report - Stock Titan
Acorn funds and Anders Hove disclose stakes in OnKure (NASDAQ: OKUR) up to 9.5% - Stock Titan
Leerink cuts OnKure stock price target on strategic shift By Investing.com - Investing.com Canada
Leerink cuts OnKure stock price target on strategic shift - investing.com
OnKure Announces $150M Private Placement and Board Changes - TipRanks
OnKure elects Dr. Liam Ratcliffe as director under Lead Investor designation - TradingView — Track All Markets
OnKure (NASDAQ: OKUR) secures $150M private placement and refocuses PI3Kα pipeline - Stock Titan
Panic Selling: Whats the profit margin of OnKure Therapeutics IncTake Profit & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
OnKure Therapeutics Sees Volatile Trading Amid Recent Developments - timothysykes.com
OKUR Shares Face Turbulence Amid Financial Downturn - StocksToTrade
OnKure Therapeutics Inc. Sees Variable Performance Amid Market Fluctuations - timothysykes.com
OnKure to sell $150M in stock to fund drug development - Daily Camera
OnKure raises $150M to advance breast cancer programs By Investing.com - Investing.com Australia
OnKure Therapeutics prices $150M oversubscribed private placement - MSN
Oppenheimer reiterates OnKure stock rating on pipeline shift By Investing.com - Investing.com India
Oppenheimer reiterates OnKure stock rating on pipeline shift - Investing.com
Aug Wrap: Is OnKure Therapeutics Inc in a bullish channelWeekly Investment Recap & Safe Swing Trade Setup Alerts - baoquankhu1.vn
OnKure Therapeutics, Inc. announced that it expects to receive $149.999126 million in funding from a group of investors - marketscreener.com
OnKure Therapeutics Stock Fluctuates With Market Shifts - StocksToTrade
Unprecedented Gains: OKUR Clinches Pivotal Industry Deal - timothysykes.com
Onkure Therapeutics to advance next-generation PI3Kα pan-mutant programs - BioWorld News
OnKure raises $150M to advance breast cancer programs - Investing.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies - GlobeNewswire
Access BiotechnologyFinancial Details - Crunchbase
OnKure Therapeutics CEO Saccomano sells $357 in stock By Investing.com - Investing.com Australia
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Down 85.2% in March - marketbeat.com
OnKure Therapeutics CFO Leverone sells $1.2k in shares - Investing.com UK
OnKure Therapeutics CFO Leverone sells $1.2k in shares By Investing.com - Investing.com Australia
Onkure Therapeutics Inc Stock (OKUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):